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ABSTRACT
Objectives: Osteoporosis is a multifactorial disease that causes a loss of bone density. However, genetic factors play an in-
creasingly important role in its development. To thoroughly understand the molecular mechanisms, polymorphic variants of 
genes candidate for osteoporosis are still being sought. The aim of our study was to investigate the influence of NFκB1 gene 
rs4648068 (A>G) and RUNX2 gene rs7771980 (-1025T>C) polymorphisms on the risk of osteoporosis.
Material and methods: A group of 675 postmenopausal Caucasian women (109 women with osteopenia, 333 with os-
teoporosis and 233 with normal T-score) were examined. The bone mineral density (BMD) at the lumbar spine (L1-L4) was 
measured by dual energy x-ray absorptiometry (DXA). The analysis of NFκB1 and RUNX2 polymorphisms was performed 
using real-time PCR method.
Results: Analysis of NFκB1 gene rs4648068 polymorphism showed that the GG genotype was slightly more frequent in 
the study groups compared to the control group. In the osteoporosis group, patients with the G allele in the genotype 
have lower bone mineral density values. For the RUNX2 rs7771980 polymorphism, in women with osteopenia we observed 
an increased incidence of TC heterozygotes compared to the control group (29.40% vs 24.90%, p > 0.05), and in women 
with osteoporosis, the TT genotype was more common (78.70% vs 73.80%, p > 0.05). No correlation was observed between 
the genotypes and the clinical parameters.
Conclusions: The analysis showed no significant relationship between the genotypic distribution and the individual 
clinical parameters. However, it is suggested an association between the rs4648068 polymorphism of the NFκB1 gene and 
an increased risk of developing osteoporosis.
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INTRODUCTION
Osteoporosis is a multifactorial, chronic metabolic dis-
ease of the skeletal system. It is characterized by a progressive 
decrease in bone density (BMD), which leads to an increased 
risk of fractures [1]. Initially, it develops asymptomatically, 
there is a painless deterioration of the state of the skeletal 
system and destruction of bone mass. Osteoporotic frac-
tures, caused as a result of light injuries, are usually the 
first noticeable symptom, indicating the very advanced 
disease [2]. The occurrence of osteoporosis depends on age, 
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race, sex and ethnicity. The incidence increases with age; 
however, most cases are observed in patients over 70 years 
of age. Osteoporosis is more common in women, especially 
in postmenopausal women (postmenopausal osteoporosis). 
The greatest risk of developing osteoporosis was observed 
in Caucasian and Asian women [2, 3].
In order to determine the genetic basis for the develop-
ment of osteoporosis, the single nucleotide polymorphisms 
involved in bone tissue metabolism, such as receptor acti-
vator for nuclear factor κ B (RANK), receptor activator for 
nuclear factor κ B ligand (RANKL) or other genes affecting 
ossification, are analyzed [4]. RANKL is a protein found on 
the surface of osteoblasts that participates in the formation 
of mature osteoclasts.
It binds RANK, located on the surface of osteoclasts, as 
a result of which these cells differentiate into mature mul-
tinucleated forms. Blocking RANKL prevents its attachment 
to a receptor that inhibits osteoclast maturation and bone 
resorption. The effect of the RANK and RANKL interaction is 
the activation of nuclear factor of activated T cells transcription 
complex 1 (NFATc1), nuclear factor κB (NFκB) i cellular Finkel-Bis-
kis-Jinkins murine osteosarcoma (cFos/Fra-1) transcription fac-
tors. The NF-κB protein family regulates the expression of many 
genes involved in various immune and inflammatory response 
processes. It includes five transcription factors NF-κB1 (also 
named p50), NF-κB2 (or p52), RelA (or p65), RelB and c-Rel [5–7]. 
It is not known exactly how NFκB affects mature osteoclasts. It 
has been found in mice that the deletion of the gene encoding 
the NFκB transcription factor, more specifically the p50 and 
p52 subunits, is responsible for osteoclast-independent, rare, 
hereditary disease marbled bone called Albers and Schõnberg 
disease or osteopetrosis [8, 9].
Another gene involved in bone formation is runt-related 
transcription factor 2 (RUNX2), located at the 6p21 locus. 
It contains two promoters P1 and P2 and seven exons and 
encodes two protein isoforms: RUNX2-I and RUNX2-II. It is 
a key transcription factor associated with osteoblast dif-
ferentiation, RUNX2-I involved in the early stages of os-
teoclastgenesis, and RUNX2-II in the process of osteoblast 
maturation. Studies have shown that mice deficient of the 
transcription factor RUNX2 did not show complete bone 
formation, and craniofacial dysplasia (CCD) was observed 
in knockout heterozygous.
The aim of our study was to check whether se-
lected polymorphisms NFκB1 rs4648068 (A>G) and 
RUNX2 rs7771980 (-1025T>C) are more common in post-
menopausal women and whether they may predispose to 
the development of osteoporosis.
MATERIAL AND METHODS
A group of 675 postmenopausal Caucasian women 
with Polish origin was examined. The patients were di-
vided into three groups: 109 women with osteopenia 
(mean age 53.24 ± 0.74 years), 333 with osteoporosis (mean 
age 56.06 ± 0.75 years) and 233 control group with normal 
T-score (mean age 53.38 ± 1.01 years). During the interview, 
information was obtained on illnesses, medications taken, 
patient’s age, reproduction age, number of pregnancies and 
birth weight, and age of first and last menstruation. Women 
with ovariectomy and taking medicines which might influ-
ence the bone metabolism (hormone therapy, selective 
modulators of estrogen receptors) as well as women with 
diseases affecting the density and loss of bone mass were 
excluded from the study.
Bone mineral density (BMD) measurements were per-
formed at the Densitometry Laboratory, Clinical Hospital 
No. 1, Pomeranian Medical University in Szczecin, using 
a densitometric apparatus — LUNAR DPX 100 (Lunar Corp., 
Madison, USA). Each woman was examined in the lumbar 
spine from L2 to L4 using DEXA (Dual Energy X-ray Absorp-
tiometry). The study determined BMD, T-score and Z-score 
parameters, as well as the average BMD YA and AM for 
young-adult and age-matched. Based on the value of the 
T-score, women were classified into the group with osteo-
penia (–2.5 < T-score < –1), osteoporosis (T-score < –2.5) 
and with the correct T-score – control group (T-score > –1). 
The study was approved by Local Bioethical Committee of 
Pomeranian Medical University in Szczecin.
The genetic analysis was performed at the Depart-
ment of Stem Cell and Regenerative Medicine, Institute 
of Natural Fibers and Medicinal Plants, Poznan. Genom-
ic DNA was isolated from the blood using a commercial 
QIAamp Blood Kit (Qiagen GmbH, Hilden, Germany) ac-
cording to the protocol. The LightCycler FastStart DNA Mas-
ter HybProbe (Roche Diagnostics) and LightCycler®96 in-
struments were used for NFκB1 and RUNX2 genotyping. 
Determination of the NFκB1 rs464806 polymorphism and 
the RUNX2 rs7771980 polymorphism was performed using 
LightSNiP NFκB1 and RUNX2 (TIBMolbiol, Germany). PCR 
was carried out according to the manufacturer’s protocol.
Data analysis was performed using SPSS Statistics 
17.0 using one-way ANOVA test. The value of p < 0.05 was 
considered as statistically significant.
RESULTS
The characteristics of clinical parameters of the study 
groups and the control group in postmenopausal wom-
en was showed in Table 1. The differences in the T-score 
and Z-score values between the groups (osteoporosis 
T-score: –3.16 ± 0.06, Z-score: –3.57 ± 1.95, osteopenia: 
T-score: 1.83 ± 0.04, Z-score: 0.84 ± 0.08, control group: 
T-score: 0.08 ± 0.11, Z-score: 0.64 ± 0.20) were observed. 
Studies have shown a correlation between the patients’ BMI 
and individual groups (osteoporosis: 23.79 ± 0.32, osteope-
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Osteopenia* –1.83 ± 0.04 –1.91 –1.75
Osteoporosis –3.16 ± 0.06 –3.28 –3.05
Controls 0.08 ± 0.11 –0.15 0.30
Z-score
Osteopenia –0.84 ± 0.08 –1.01 –0.68
Osteoporosis –3.57 ± 1.95 –7.46 0.32
Controls 0.64 ± 0.20 0.24 1.04
Body mass
[kg]
Osteopenia* 65.17 ± 1.00 63.20 67.14
Osteoporosis 61.21 ± 0.94 59.35 63.07
Controls 68.73 ± 1.49 65.75 71.71
Height
[cm]
Osteopenia* 162.63 ± 0.45 161.74 163.52
Osteoporosis 160.25 ± 0.53 159.20 161.30
Controls 163.08 ± 0.74 161.61 164.55
BMI 
[kg/m2]
Osteopenia* 24.64 ± 0.36 23.94 25.35
Osteoporosis 23.79 ± 0.32 23.16 24.42
Controls 25.88 ± 0.56 24.77 26.99
Age 
[years]
Osteopenia* 53.24 ± 0.74 51.78 54.69
Osteoporosis 56.06 ± 0.75 54.59 57.54
Controls 53.38 ± 1.01 51.36 55.40
Birth weight 
[g]
Osteopenia* 3226.79 ± 77.68 3067.39 3386.18
Osteoporosis 3141.25 ± 134.08 2855.47 3427.03
Controls 3628.95 ± 110.29 3397.23 3860.66
Years of 
reproduction
Osteopenia 36.20 ± 0.64 34.93 37.47
Osteoporosis 35.62 ± 0.62 34.37 36.86
Controls 36.38 ± 0.95 34.45 38.30
Age of first 
menstruation
Osteopenia 13.12 ± 0.31 12.50 13.74
Osteoporosis 12.94 ± 0.27 12.40 13.47
Controls 13.38 ± 0.33 12.70 14.05
Age of last 
menstruation
Osteopenia 49.21 ± 0.50 48.22 50.20
Osteoporosis 48.16 ± 0.55 47.07 49.25
Controls 50.17 ± 0.69 48.79 51.56
Number of 
pregnancies
Osteopenia 1.89 ± 0.10 1.69 2.08
Osteoporosis 1.96 ± 0.14 1.69 2.22
Controls 1.94 ± 0.04 1.64 2.24
Years after 
menopause
Osteopenia* 7.18 ± 0.11 5.63 8.74
Osteoporosis 10.63 ± 0.08 9.21 12.06
Controls 7.03 ± 0.08 5.02 9.05
BMD
L2-L4 [g/cm2]
Osteopenia 0.97 ± 0.20 0.93 1.01
Osteoporosis 0.98 ± 0.81 0.95 1.00
Controls 0.97 ± 1.00 0.93 1.01
BMD 
L2-L4 YA [%]
Osteopenia 80.90 ± 1.49 77.49 84.32
Osteoporosis 81.28 ± 0.66 78.82 83.74
Controls 81.02 ± 0.45 77.46 84.59
BMD L2-L4 AM [%]
Osteopenia 89.13 ± 0.74 85.50 92.76
Osteoporosis 89.50 ± 0.32 87.07 91.94
Controls 89.78 ± 0.36 85.88 93.67
*p < 0.05 — comparison between the groups with osteopenia/osteoporosis and normal T-score (one-way ANOVA); BMI — body mass index; BMD — bone mineral density
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nia: 24.64 ± 0.36 vs control group: 25.88 ± 0.56, p < 0.05). 
A similar relationship was observed for birth weight (osteo-
porosis: 3141.25 ± 134.08 g, osteopenia: 3226.78 ± 77.68 g 
vs control group: 3628.95 ± 110.29 g, p < 0.05). Other clinical 
parameters do not differ significantly between the study 
groups and the control group.
The genotype distribution of the NFκB1 (rs4648068) and 
RUNX2 (rs7771980) polymorphisms between the groups was 
analyzed (Tab. 2 and 3). For the NFκB1 rs4648068 polymor-
phism, no significant differences were observed between 
the genotypes in the individual groups. The GG genotype 
was slightly more frequent in the study groups than in the 
control group (osteoporosis 11.40%, osteopenia 10.10% vs 
control group 8.20%, p > 0.05). In the case of rs7771980 poly-
morphism of the RUNX2 gene in women with osteopenia, 
a higher frequency of TC heterozygotes was observed com-
pared to the control group (29.40% vs 24.90%, p > 0.05), 
and in the group with osteoporosis the most common was 
the TT genotype (78.70% vs 73.80%, p > 0.05). There was no 
statistically significant difference between the distribution 
of genotypes of the studied polymorphism in the control 
and tested groups. No correlation was observed between 
genotype occurrence and osteoporosis development.
In addition, an analysis of the correlation between the 
NFκB1 rs464806 and RUNX2 rs7771980 polymorphisms 
with clinical parameters was performed (Tab. 4 and 5). 
The analysis did not show any statistical significance be-
tween the genotypic distribution and the individual clini-
cal parameters analyzed. In the case of the NFκB1 poly-
morphism, lower BMI values were observed for patients 
with the G allele in the genotype in both osteopenia and 
osteoporosis. Patients with the GG genotype had a higher 
birth weight compared to the other genetic variants tested. 
It has been shown that women with the G allele in the os-
teoporosis group have lower bone mineral density values. 
It is suggested that the G allele in the genotype is associ-
Table 3. The frequency of alleles and genotypes of RUNX2 polymorphism (rs7771980) in the group of women with osteopenia, osteoporosis 















TT 77 (70.60) 72.76 262 (78.70) 78.15 172 (73.80) 74.50
TC 32 (29.40) 25.08 65 (19.50) 20.51 58 (24.90) 23.60
CC 0 2.16 6 (1.80) 1.35 3 (1.30) 1.90
Total 109 (100%) 100.00 333 (100%) 100.00 233 (100%) 100.00
Allele
T 186 (85.30) – 589 (88.40) – 402 (86.30) –
C 32 (14.70) – 77 (11.60) – 64 (13.70) –
Total 218 (100.00) – 666 (100.00) – 466 (100.00) –
Table 2. The frequency of alleles and genotypes of NFκB1 polymorphism (rs4648068) in the group of women with osteopenia, osteoporosis 















AA 46 (42.20) 43.70 145 (43.50) 43.70 106 (45.50) 47.20
AG 52 (47.70) 44.80 150 (45.00) 44.80 108 (46.40) 43.00
GG 11 (10.10) 11.50 38 (11.40) 11.50 19 (8.20) 9.80
Total 109 (100%) 100.00 333 (100%) 100.00 233 (100%) 100.00
Allele
A 144 (66.10) – 440 (66.10) – 320 (68.70) –
G 74 (33.90) – 226 (33.90) – 146 (31.30) –
Total 218 (100.00) – 666 (100.00) – 466 (100.00) –
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Table 4. Characteristics of the postmenopausal women with normal T-score, osteopenia and osteoporosis taking part in the study of the 
rs4648068 polymorphism of NFκB1 gene
Genotype
Mean ± SEM Mean ± SEM Mean ± SEM
AA AG GG
Controls
T-score –0.11 ± 0.13 0.13 ± 0.19 0.83 ± 0.55
Z-score 0.51 ± 0.28 0.65 ± 0.30 1.17 ± 0.76
Body mass [kg] 66.44 ± 2.46 69.83 ± 2.08 75.40 ± 5.33
BMI [kg/m2] 25.34 ± 0.83 26.45 ± 0.86 27.33 ± 2.41
Birth weight [g] 3587.50 ± 255.26 3.715.00 ± 70.10 3510.00 ± 141.77
BMD L2–L4 [g/cm2] 0.98 ± 0.03 0.96 ± 0.04 1.03 ± 0.04
BMD L2–L4 YA [%] 81.64 ± 2.86 80.15 ± 2.90 85.25 ± 2.95
BMD L2–L4 AM [%] 91.23 ± 2.97 89.30 ± 3.39 91.00 ± 2.04
Osteopenia
T-score –1.79 ± 0.06 –1.80 ± 0.06 –1.90 ± 0.14
Z-score –0.86 ± 0.14 –0.81 ± 0.13 –0.92 ± 0.18
Body mass [kg] 66.71 ± 1.94 64.52 ± 1.42 64.36 ± 1.88
BMI [kg/m2] 25.19 ± 0.71 24.27 ± 0.49 24.43 ± 0.63
Birth weight [g] 3290.00 ± 129.25 3148.57 ± 119.18 3342.50 ± 156.70
BMD L2–L4 [g/cm2] 0.93 ± 0.04 0.99 ± 0.03 0.99 ± 0.04
BMD L2–L4 YA [%] 77.82 ± 3.45 82.51 ± 2.53 82.50 ± 3.01
BMD L2–L4 AM [%] 86.33 ± 3.62 89.85 ± 2.60 92.00 ± 3.95
Osteoporosis
T-score –3.13 ± 0.08 –3.20 ± 0.09 –3.39 ± 0.21
Z-score –1.71 ± 0.15 –6.10 ± 4.52 –1.37 ± 0.21
Body mass [kg] 62.58 ± 1.43 60.45 ± 1.54 57.57 ± 2.72
BMI [kg/m2] 24.11 ± 0.47 23.52 ± 0.54 23.52 ± 1.08
Birth weight [g] 3220.00 ± 298.50 3010.00 ± 53.63 3600.00 ± 600.00
BMD L2–L4 [g/cm2] 1.02 ± 0.03 0.96 ± 0.02 0.92 ± 0.02
BMD L2–L4 YA [%] 84.80 ± 2.35 80.16 ± 1.80 76.33 ± 2.00
BMD L2–L4 AM [%] 93.14 ± 2.39 88.24 ± 1.69 85.87 ± 2.28
Data are mean ± SEM values. None of the parameters showed any significant difference among the genotypes; *p value < 0.05; SEM — standard error of the mean;  
BMI — body mass index; BMD — bone mineral density
ated with an increased risk of developing osteoporosis and 
may predispose to its development. For the RUNX2 poly-
morphism, no correlation between genotype and clinical 
parameter was observed.
DISCUSSION
Osteoporosis is a multifactorial disease associated with 
low bone mass and increased risk of fractures. However, 
the genetic factors may play a large role in its develop-
ment. Despite ongoing research, little is known about the 
genetic mechanisms that control bone growth and forma-
tion. To thoroughly understand the molecular mechanisms, 
polymorphic variants of genes candidate for osteoporosis 
are still being sought [10]. In our study, the association of 
NFκB1 rs4648068 and RUNX2 rs7771980 polymorphisms 
with osteoporosis was analyzed. Based on the frequency 
distribution of individual genotypes and alleles, an attempt 
was made to determine the genotype or allele predisposing 
to this disease.
Analyzing the NFκB1 A>G polymorphism, a slightly more 
frequent occurrence of the GG genotype was observed in 
women with osteopenia and osteoporosis compared to 
control group with normal T-score (osteoporosis 11.40%, 
osteopenia 10.10% vs control group 8.20%). Patients with 
the G allele in the osteoporosis group showed lower bone 
mineral density values, suggesting that the G allele is as-
sociated with an increased risk of developing osteoporosis. 
So far, the impact of the rs4648068 NFκB1 gene polymor-
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phism in the Caucasian group on the development of osteo-
porosis has not been analyzed. The NFκB transcription factor 
and its effect on the skeletal system are still under investiga-
tion. It has been discovered that the deletion of the gene 
encoding NFκB in mice, more specifically the p50 (NFκB1) 
and p52 (NFκB2) subunits, is responsible for rare, hereditary 
osteopetrosis [11]. Therefore, our studies were undertaken 
to look for a new genetic marker that could differentiate 
patients with an increased predisposition to developing 
osteoporosis.
For the rs7771980 polymorphism of the RUNX2 gene, the 
TC genotype was more frequent in the osteopenia group 
compared to the control group, and the TT genotype was 
more common in the osteoporosis group. No correlation 
Table 5. Characteristics of the postmenopausal women with normal T-score, osteopenia and osteoporosis taking part in the study of the 
rs7771980 polymorphism of RUNX2 gene
Genotype
Mean ± SEM Mean ± SEM Mean ± SEM
TT TC CC
Controls
T-score 0.04 ± 0.14 0.26 ± 0.23 –0.95 ± 0.35
Z-score 0.46 ± 0.26 1.01 ± 0.29 –0.35 ± 0.12
Body mass [kg] 66.80 ± 1.52 74.00 ± 3.95 76.00 ± 3.86
BMI [kg/m2] 25.27 ± 0.59 27.95 ± 1.40 30.33 ± 1.12
Birth weight [g] 3582.14 ± 98.52 3812.50 ± 430.30 3550.00 ± 325.5
BMD L2–L4 [g/cm2] 0.97 ± 0.03 1.00 ± 0.05 0.79 ± 0.04
BMD L2–L4 YA [%] 80.82 ± 2.23 83.92 ± 3.44 66.50 ± 2.45
BMD L2–L4 AM [%] 90.70 ± 2.27 91.25 ± 4.44 69.40 ± 3.12
Osteopenia
T-score –1.81 ± 0.05 –1.80 ± 0.08 –
Z-score –0.88 ± 0.09 –0.74 ± 0.21 –
Body mass [kg] 65.70 ± 1.31 64.75 ± 1.87 –
BMI [kg/m2] 24.88 ± 0.47 24.18 ± 0.66 –
Birth weight [g] 3189.52 ± 75.98 3338.57 ± 219.35 –
BMD L2–L4 [g/cm2] 0.96 ± 0.02 0.97 ± 0.06 –
BMD L2–L4 YA [%] 79.94 ± 1.67 81.88 ± 4.80 –
BMD L2–L4 AM [%] 88.13 ± 1.78 89.62 ± 4.95 –
Osteoporosis
T-score –3.19 ± 0.07 –3.15 ± 0.11 –2.84 ± 0.05
Z-score –4.16 ± 2.53 –1.68 ± 0.16 –0.72 ± 0.21
Body mass [kg] 61.23 ± 1.16 61.39 ± 2.03 57.50 ± 2.45
BMI [kg/m2] 23.85 ± 0.38 23.71 ± 0.74 22.26 ± 0.67
Birth weight [g] 3095.00 ± 148.70 3410.00 ± 384.30 3050.20 ± 285.40
BMD L2–L4 [g/cm2] 0.97 ± 0.02 1.02 ± 0.04 0.98 ± 0.14
BMD L2–L4 YA [%] 80.53 ± 1.40 85.27 ± 3.44 81.67 ± 11.70
BMD L2–L4 AM [%] 89.11 ± 1.42 92.91 ± 3.38 91.00 ± 8.74
Data are mean ± SEM values. None of the parameters showed any significant difference among the genotypes; *p value < 0.05; SEM — standard error of the mean;  
BMI — body mass index; BMD — bone mineral density
was observed between the genotype and the clinical pa-
rameters, which would indicate a predisposition to the 
development of osteoporosis. Bustamante et al. studied 
the effects of -330 G>T polymorphism in promoter P1 and 
-1025 T>C polymorphism (rs7771980) in promoter P2 of 
RUNX2 in 821 Spanish postmenopausal women. The analysis 
showed that the -330 G>T polymorphism was not associated 
with any of the phenotypes analyzed, and the -1025 T>C 
polymorphism was associated with bone mineral density 
in the femoral neck (FN BMD). Patients with TC genotype 
had higher mean corrected FN BMD values than patients 
with TT genotype. No relationship was found between 
the -1025 T>C polymorphism and bone mineral density 
in the lumbar spine (LS BMD). Due to the small size of the 
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group with the CC genotype, no association with FN BMD 
was observed [12]. Lee et al. analyzed two RUNX2 polymor-
phisms: -1492 A>T and -1025 T>C among 729 Korean post-
menopausal women. In this study, no significant relationship 
between the -1492 A>T polymorphism and BMD was found. 
The analysis showed a significant relationship between the 
CC genotype and the reduced bone mineral density in the 
lumbar spine and femoral neck compared to TC heterozy-
gotes and TT homozygotes [13].
In another study, Pined’s team investigated the effect of 
-1025 T>C polymorphism (rs7771980) of the RUNX2 gene on 
the development of osteoporosis in 776 Spanish postmeno-
pausal women. Like earlier researchers, they observed the 
relationship of polymorphism with BMD FN, but not with 
BMD LS. Women with the TC genotype had a higher BMD 
FN than women with the TT genotype. Unlike previous re-
searchers, they found a relationship between CC genotype 
and higher BMD FN than women with TT genotype [14].
In addition, various researchers suggest that several 
other RUNX2 gene polymorphisms are associated with the 
development of osteoporosis. Auerkari et al. [10] studied 
the variability of -330 G>T (rs59983488) polymorphism 
in 180 Indonesian postmenopausal women. It has been 
shown that the TT genotype is associated with an increased 
risk of developing osteoporosis. Vaughan’s team studied 
-336G>A polymorphism of the RUNX2 gene in 991 Scottish 
postmenopausal women. Their data suggest that RUNX2 al-
leles are associated with BMD in a manner dependent on 
menopause and body mass [16].
CONSLUSIONS
In conclusion, based on the literature data, no definite 
conclusions can be drawn. The NFκB1 gene rs4648068 poly-
morphism has not yet been studied in connection with the 
development of osteoporosis. Our studies have shown that 
the G allele in the genotype is associated with an increased 
risk of developing osteoporosis and may predispose to its 
development. Probably the RUNX2 gene rs7771980 poly-
morphism predisposes to the development of osteoporosis, 
but our studies have not confirmed this fact. Additional stud-
ies are required to confirm these relationships. All progress 
in this field has great potential, because understanding the 
mechanisms leading to the development of osteoporosis 
could allow the creation of effective therapies and the intro-
duction of appropriate drugs. Early diagnosis of the disease 
and the implementation of appropriate treatment adapted 
to the genotype of patients can slow down or completely 
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